Unmet Need
Oxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure.
Technology Overview
Disclosed herein are novel metal nanozymes to treat α-synucleinopathies. The reported compounds possess strong scavenging ability on oxidative stress, thereby blocking the aggregation of pathogenic prion-like α-syn and tau. Pre-clinical in vitro and in vivo proof of concept validated the strong ROS scavenging ability and inhibitory effect of the nanozymes on α-syn aggregation.
Stage of Development
In vitro and in vivo preclinical proof of concept.
